In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

Based on a small trial with positive muscle performance data, Regenxbio is expected to pursue approval of its gene therapy ...

Republicans have despised the Affordable Care Act since its inception almost 15 years ago. But some health care executives ...

Nothing brought Olivia more joy than when her daughter and grandchild visited her group home in Brooklyn in the early 2000s.

The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with a ...

CHICAGO — In his presidential address to the American Heart Association on Sunday, Keith Churchwell, a clinical cardiologist ...

Cancer cases are on the rise among people under 50 — and researchers aren’t sure why. A recent study by the American Cancer ...

California has detected the country’s first case of a new mpox strain in a person who recently traveled from Eastern Africa ...

Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.

Trump's HHS pick could reshape public health agencies and usher in a new era for vaccines, food, and medicines.

The DEA grants a one-year extension on telehealth prescription of addiction medications, kicking resolution on a fraught ...

WASHINGTON — Robert F. Kennedy Jr., President-elect Trump’s nominee for secretary of Health and Human Services, has ...